SANTA CLARA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper Sandler 35th Annual Healthcare Conference, which is being held from Tuesday, November 28 to Thursday, November 30, 2023 in New York, NY.
Shockwave management is scheduled for a live fireside chat on Wednesday, November 29, 2023, at 1:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at: https://ir.shockwavemedical.com.
About Shockwave Medical, Inc.
Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.
Media Contact:
Scott Shadiow
+1.317.432.9210
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Debbie Kaster
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$330.38 |
| Daily Change: | 0.38 0.12 |
| Daily Volume: | 633,962 |
| Market Cap: | US$12.390B |
April 08, 2024 January 29, 2024 November 09, 2023 November 06, 2023 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
